2654. International Multi-Center Study Comparing the Effect of Obinutuzumab or Rituximab Treatment in Hematological Patients on COVID-19 Outcomes During the Omicron Surge

BACKGROUND: Hematological malignancy (HM) patients treated with anti-CD20 monoclonal antibodies are at higher risk for severe COVID-19 and adverse outcomes. A previous single-center study showed worse outcomes in patients treated with obinutuzumab than those treated with rituximab. METHODS: This is...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafat, Tal, Grupel, Daniel, Porges, Tzvika, Belkin, Ana, Deri, Ofir, Oster, Yonatan, Zahran, Shadi, Horwitz, Ehud, Horowitz, Netanel A, Khatib, Hazim, Batista, Marjorie, Cortez, Anita, Brosh-Nissimov, Tal, Segman, Yafit, Ishay, Linor, Cohen, Regev, Atamna, Alaa, Spallone, Amy, Chemaly, Roy F, Ramos, Juan Carlos, Chowers, Michal, Rogozin, Evgeny, Carmi-Oren, Noga, Keske, Şiran, Barchad, Orit Wolfovitz, Nesher, Lior
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679282/
http://dx.doi.org/10.1093/ofid/ofad500.2265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679282/
http://dx.doi.org/10.1093/ofid/ofad500.2265

Ejemplares similares